High concordance of the Company's Target-Selector™ platform enables real-time monitoring of key biomarkers in metastatic breast cancer, and provides an alternative when tissue biopsy is not an option
Results demonstrate high level of analytical sensitivity and specificity for the Company's non-invasive, clinically actionable biomarker test for immunotherapy
SAN DIEGO , Nov. 21, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that President and CEO
Revenues increased 58% sequentially to a record highCommercial sample volume more than doubled versus prior year period9 consecutive quarters of growth in total sample volumeCompany to host conference call at 4:30 p.m. Eastern time today
SAN DIEGO , Oct. 31, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that it will release
SAN DIEGO , Oct. 27, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces the appointment of David
Target Selector™ platform delivers 90% concordance and capability to rapidly detect EGFR, ALK, BRAF, and ROS1 alterations in non-small cell lung cancer patients
SAN DIEGO , Oct. 19, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to provide information to physicians to improve the diagnosis and treatment of cancer, announces the closing of its previously
SAN DIEGO , Oct. 14, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to provide information to physicians to improve the diagnosis and treatment of cancer, announces the pricing of an underwritten public
In the news release, Clinical Results Demonstrating the Performance of Biocept's Target Selector Platform to be Presented at the 2016 European Society of Medical Oncology Annual Congress, issued 29-Sep-2016 by Biocept, Inc. over PR Newswire, we are advised by the company that the first paragraph,
